Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Apr 02, 2024 (filed on Apr 04, 2024)Insider Name:Ra Capital Management, L.P.Ownership Type:Indirect OwnershipSecurities:Series C Preferred StockNature of Transaction:C - Conversion# or value acquired/disposed of:-2,464,286Price:--
-
Apr 02, 2024 (filed on Apr 04, 2024)Insider Name:Ra Capital Management, L.P.Ownership Type:Indirect OwnershipSecurities:Series C Preferred StockNature of Transaction:C - Conversion# or value acquired/disposed of:-13,964,285Price:--
-
Apr 02, 2024 (filed on Apr 04, 2024)Insider Name:Ra Capital Management, L.P.Ownership Type:Indirect OwnershipSecurities:Series B Preferred StockNature of Transaction:C - Conversion# or value acquired/disposed of:-3,000,000Price:--
-
Apr 02, 2024 (filed on Apr 04, 2024)Insider Name:Ra Capital Management, L.P.Ownership Type:Indirect OwnershipSecurities:Series B Preferred StockNature of Transaction:C - Conversion# or value acquired/disposed of:-17,000,000Price:--
-
Apr 02, 2024 (filed on Apr 04, 2024)Insider Name:Ra Capital Management, L.P.Ownership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:15,625Price:$16.00
-
Apr 02, 2024 (filed on Apr 04, 2024)Insider Name:Ra Capital Management, L.P.Ownership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:C - Conversion# or value acquired/disposed of:280,219Price:--
-
Apr 02, 2024 (filed on Apr 04, 2024)Insider Name:Ra Capital Management, L.P.Ownership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:296,875Price:$16.00
-
Apr 02, 2024 (filed on Apr 04, 2024)Insider Name:Ra Capital Management, L.P.Ownership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:C - Conversion# or value acquired/disposed of:1,587,912Price:--
-
Apr 02, 2024 (filed on Apr 02, 2024)Insider Name:Wellington Biomedical Innovation Master Investors (Cayman) I L.P.Ownership Type:Direct OwnershipSecurities:Series C Preferred StockNature of Transaction:C - Conversion# or value acquired/disposed of:-7,142,857Price:--
-
Apr 02, 2024 (filed on Apr 02, 2024)Insider Name:Wellington Biomedical Innovation Master Investors (Cayman) I L.P.Ownership Type:Direct OwnershipSecurities:Series B Preferred StockNature of Transaction:C - Conversion# or value acquired/disposed of:-3,703,704Price:--
Filings by filing date
-
Apr 02, 2024 (filed on Apr 04, 2024)Insider Name:Ra Capital Management, L.P.Ownership Type:Indirect OwnershipSecurities:Series C Preferred StockNature of Transaction:C - Conversion# or value acquired/disposed of:-2,464,286Price:--
-
Apr 02, 2024 (filed on Apr 04, 2024)Insider Name:Ra Capital Management, L.P.Ownership Type:Indirect OwnershipSecurities:Series C Preferred StockNature of Transaction:C - Conversion# or value acquired/disposed of:-13,964,285Price:--
-
Apr 02, 2024 (filed on Apr 04, 2024)Insider Name:Ra Capital Management, L.P.Ownership Type:Indirect OwnershipSecurities:Series B Preferred StockNature of Transaction:C - Conversion# or value acquired/disposed of:-3,000,000Price:--
-
Apr 02, 2024 (filed on Apr 04, 2024)Insider Name:Ra Capital Management, L.P.Ownership Type:Indirect OwnershipSecurities:Series B Preferred StockNature of Transaction:C - Conversion# or value acquired/disposed of:-17,000,000Price:--
-
Apr 02, 2024 (filed on Apr 04, 2024)Insider Name:Ra Capital Management, L.P.Ownership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:15,625Price:$16.00
-
Apr 02, 2024 (filed on Apr 04, 2024)Insider Name:Ra Capital Management, L.P.Ownership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:C - Conversion# or value acquired/disposed of:280,219Price:--
-
Apr 02, 2024 (filed on Apr 04, 2024)Insider Name:Ra Capital Management, L.P.Ownership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:296,875Price:$16.00
-
Apr 02, 2024 (filed on Apr 04, 2024)Insider Name:Ra Capital Management, L.P.Ownership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:C - Conversion# or value acquired/disposed of:1,587,912Price:--
-
Apr 02, 2024 (filed on Apr 04, 2024)Insider Name:Burow KristinaOwnership Type:Indirect OwnershipSecurities:Series B Convertible Preferred StockNature of Transaction:C - Conversion# or value acquired/disposed of:-227,920Price:--
-
Apr 02, 2024 (filed on Apr 04, 2024)Insider Name:Burow KristinaOwnership Type:Indirect OwnershipSecurities:Series A Convertible Preferred StockNature of Transaction:C - Conversion# or value acquired/disposed of:-454,212Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 9880 Campus Point Drive, Suite 120 SAN DIEGO CA 92121 |
Tel: | N/A |
Website: | https://boundlessbio.com |
IR: | See website |
Key People | ||
Zachary D. Hornby President, Chief Executive Officer, Director | Jami E. Rubin Chief Financial Officer | Christian Hassig Chief Scientific Officer |
Neil Abdollahian Chief Business Officer | Klaus Wagner Chief Medical Officer | Jessica Oien Chief Legal Officer and Corporate Secretary |
Business Overview |
Boundless Bio, Inc. is a clinical-stage oncology company, which is engaged in cancer therapeutics that addresses the unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA). Using its proprietary Spyglass platform, it identifies targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. Its lead ecDTx, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. BBI-355 demonstrated CHK1 inhibition and tumor regressions in ecDNA-enabled preclinical cancer models and is being studied in a first-in-human, Phase I/II clinical trial in patients with oncogene amplified cancers. Its second ecDTx, BBI-825, is an oral, selective inhibitor of ribonucleotide reductase, which is essential for ecDNA assembly and repair in cancer cells. |
Financial Overview |
For the fiscal year ended 31 December 2023, Boundless Bio Inc revenues was not reported. Net loss increased 8% to $49.4M. Higher net loss reflects Biotechnology & Medical Research segment loss increase of 18% to $54.8M. Basic Earnings per Share excluding Extraordinary Items decreased from -$2.06 to -$2.22. |
Employees: | 72 as of Mar 1, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $395.29M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$53.80M as of Dec 31, 2023 |
Net annual income (TTM): | -$49.43M as of Dec 31, 2023 |
Free cash flow (TTM): | -$47.49M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 22,239,333 as of Mar 21, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |